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Another Battlefield for
the NAD(P)H Oxidase?*
Ascan Warnholtz, MD, Thomas Munzel, MD
Hamburg, Germany
Chronic congestive heart failure (CHF) is a clinical syn-
drome characterized by progressive left ventricular (LV)
systolic and/or diastolic dysfunction. Recent studies point to
a crucial role of oxidative stress as the underlying mecha-
nism being at least in part responsible for ventricular
dysfunction (1). Excess production of reactive oxygen spe-
cies (ROS) may alter the activity and/or expression of
proteins involved in the excitation–contraction coupling,
such as sarcolemmal ion channels (2), ion exchangers (3),
sarcoplasmic reticulum calcium release channels (4), and
myofilament proteins (5), all of which may contribute to
myocardial contractile dysfunction. These in vitro findings
were supported by a recent in vivo study by Ide et al. (6). In
an animal model of CHF, the authors found that rapid
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ventricular pacing for a four-week period markedly in-
creased ROS levels such as superoxide anions, hydroxyl
radicals, and hydrogen peroxide in canine myocardial tissue
homogenates. There was a significant positive correlation
between myocardial ROS levels and LV contractile dysfunc-
tion (6). In patients with heart failure, pericardial levels of
8-iso-PGF2 (isoprostanes, a marker for ROS production)
correlate closely with the functional severity of heart failure
(HF) and with end-systolic and end-diastolic diameters of
the LV (7). Increased ROS production within the myocar-
dium of hearts from experimental models of CHF may also
be due to impaired antioxidant defense capacity (8), as
demonstrated by reduced activity of Cu/Zn superoxide
dismutase (9,10) and catalase (11), respectively.
In the setting of CHF, increased ROS production may
arise from different enzymatic sources, including the xan-
thine oxidase (12), the mitochondria (13), the cyclooxygen-
ase, the nitric oxide synthase, and the non-phagocytic
NAD(P)H oxidase. During the past decade it has become
evident that the NAD(P)H-driven oxidase plays an impor-
tant pathogenetic role in vascular tissue. In the presence of
cardiovascular risk factors for the development of athero-
sclerosis, such as hypercholesterolemia (14), hypertension
(15), and diabetes mellitus (16), endothelial dysfunction in
animal models as well as in human vascular tissue from
human patients (17,18) was consistently shown to be
associated with increased NAD(P)H oxidase-mediated vas-
cular superoxide production. Vascular endothelial and ad-
ventitial cells, as well as inflammatory cells such as neutro-
phils and macrophages, express the NAD(P)H oxidase,
which consists of the flavocytochrome b558 subunits
gp91phox and p22phox as well as the cytosolic factors p47phox
and p67phox and the small GTPase rac1 (19,20). In contrast
to endothelial, adventitial, and inflammatory cells, smooth
muscle cells of large arteries lack gp91phox, but recent studies
identified the existence of two gp91phox homologues,
namely nox-1 and nox-4 (21,22). Activity and expression of
the vascular non-phagocytic enzyme have been found to
increase upon stimulation with angiotensin II, aldosterone,
endothelin-1, and cytokines such as tumor necrosis factor
alpha (TNF-). Because plasma levels of these neurohor-
mones and cytokines are increased in the setting of CHF, it
is tempting to speculate that a similar phenomenon may also
apply to cardiomyocytes of the failing heart. Indeed, incu-
bation of cardiomyocytes with angiotensin II and TNF-
increases ROS production and causes cell enlargement,
which was effectively suppressed by antioxidants and cata-
lase (23). In contrast to vascular tissue (15), catecholamine-
stimulated hypertrophic signaling in cultured cardiomyo-
cytes involves NAD(P)H oxidase-mediated superoxide
production (24). More recently, Bendall et al. (25) provided
evidence that the hypertrophic response of the myocardium to
subpressor doses of angiotensin II is pivotally regulated by the
myocardial NAD(P)H oxidase, because this phenomenon was
completely prevented in gp91phox/ mice. Using a guinea
pig model of progressive LV hypertrophy, the same group
revealed increased expression of the NAD(P)H oxidase sub-
units p22phox, gp91phox, p67phox, and p47phox as well as an
activation of the oxidase during progression of cardiac hyper-
trophy to failure (26). However, up to now, the evidence of
whether the enzyme exists in human myocardium and whether
it is regulated in the setting of HF was still lacking.
In this issue of the Journal, Heymes et al. (27) for the first
time provide evidence of the activation and expression of the
NAD(P)H oxidase in human cardiomyocytes. They were
able to detect the expression of NAD(P)H oxidase subunits
p22phox, gp91phox, p67phox, and p47phox both at the messen-
ger ribonucleic acid and protein level in non-failing and
failing human myocardium. Immunohistochemical staining
for the catalytic subunit gp91phox and the regulatory subunit
p47phox revealed co-localization with cardiomyocytes. In
cardiomyocytes of non-failing hearts, gp91phox was primar-
ily co-localized with sarcolemmal membranes, and p47phox
was localized in the cytosol. Even though the overall level of
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expression was unaltered in failing compared with non-
failing myocardium, the rate of superoxide production was
significantly increased in total tissue homogenates of failing
hearts (27). Activation of the NAD(P)H oxidase requires
the translocation of the p47phox subunit to the myocyte
membrane. Accordingly, Heymes et al. (27) detected sig-
nificantly enhanced p47phox staining in sarcolemmal mem-
branes in failing myocardium, indicating translocation of
p47phox from the cytosol to cardiomyocyte membranes.
These findings are not surprising but provide support for the
hypothesis that the NAD(P)H oxidase plays a significant
role in myocardial superoxide production in the failing
human heart and therefore opens an area of further research
required to determine the functional relevance of an acti-
vated NAD(P)H oxidase for the pathogenesis of HF.
Although the authors provide evidence for an increase in
NAD(P)H oxidase–mediated superoxide production in the
failing human heart, no information concerning functional
consequences was provided. It would be of particular inter-
est to investigate, for example, the effect of targeted
NAD(P)H subunit disruption (gp91phox or p47phox knock-
out) on myocardial contractility, remodeling, and apoptosis
in HF models. It remains to be elucidated whether the
NAD(P)H oxidase of cardiomyocytes is composed exclu-
sively of phagocytic type subunits or whether there is
evidence for an expression of non-phagocytic gp91phox
(nox-2) isoforms, nox-1, -3, -4, or -5. Because the activity
of the enzyme was measured in total tissue homogenates, it
remains to be established to what extent cardiomyocytes versus
vascular tissue versus fibroblasts contribute to the observed
increases in NAD(P)H-driven superoxide production. Further
questions may include to what extent the activity and expres-
sion of the myocardial NAD(P)H oxidase is inhibited by in
vivo treatment with angiotensin-converting enzyme inhibitors,
AT1- receptor antagonists, anti-TNF antibodies, and
-receptor blockers, all of which have been shown to improve
myocardial function as well as prognosis (except for TNF-
antibodies) in patients with CHF.
Taken together, the important and new information
provided by Heymes et al. (27) points to a significant role of
the NAD(P)H oxidase in myocardial ROS production.
Increased myocardial ROS production may decrease myo-
cardial nitric oxide bioavailability, which could lead to
increased myocardial oxygen consumption (28) and to an
impairment of diastolic function (29). The reaction product
of nitric oxide and superoxide, peroxynitrite, may cause an
inactivation of the sarcoplasmatic Ca2-ATPase and sub-
sequently a dysregulation of Ca2-homeostasis within the
myocardium, as recently demonstrated for cytokine-induced
myocardial contractile failure (30,31). Thus, therapeutic
strategies to modulate this detrimental response should be a
target of future research. Finally, studies like those of
Heymes et al. shed light on mechanisms whereby proven
therapies benefit myocardial dysfunction in HF.
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